Advertisement

New Therapeutic Perspectives in Premature Ejaculation

  • Joana Simões Paço
    Affiliations
    Health Sciences School, Beira Interior University (FCS-UBI), Covilhã, Portugal
    Search for articles by this author
  • Bruno Jorge Pereira
    Correspondence
    Address correspondence to: Bruno Jorge Pereira, M.D., F.E.B.U., F.E.C.S.M., Rua Maria Victoria Bourbon Bobone Lote 22.2 Apartamento 231, 3030-502 Coimbra, Portugal.
    Affiliations
    the Department of Urology of Pêro da Covilhã Hospital, Cova da Beira Hospital Centre (CHCB), Covilhã, Portugal
    Search for articles by this author
Published:November 25, 2015DOI:https://doi.org/10.1016/j.urology.2015.11.003

      Objective

      To review potential therapeutic targets and future therapeutic molecules in premature ejaculation (PE). PE is the most prevalent sexual dysfunction and affects about 23% of the male population. It is a universal disorder: it is independent of age and social or marital status. Men with PE typically refer associated comorbidities and report a significant impact not only on their quality of life but also on the satisfaction of the partner. Although common and treatable in most cases, the drugs currently available may affect sexual spontaneity and the cost can prove to be a hindrance.

      Materials and Methods

      A comprehensive literature revision was performed using PubMed and Scopus to identify relevant articles published in the fields of PE and its treatment until May 2015.

      Results

      The main central targets identified include serotonergic, dopaminergic, and oxytocinergic neurotransmitters, opioid receptors, and mechanisms involved in the control of the spinal ejaculatory generator, located at the T12–L1-2 spinal cord level. On the other hand, peripheral interventions at semen's transport may also delay ejaculation by decreasing sequential contractions of the epididymis, vas deferens, seminal vesicles, prostate, and bladder neck.

      Conclusion

      There is a wide range of future options with regard to the treatment of PE. Molecules like DA-8031, Promescent, silodosin, Botulinum toxin-A, and resiniferatoxin may be near future treatments for this disorder.
      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to Urology
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • Giuliano F.
        Neurophysiology of erection and ejaculation.
        J Sex Med. 2011; 8: 310-315
        • Clément P.
        • Peeters M.
        • Bernabé J.
        • Denys P.
        • Alexandre L.
        • Giuliano F.
        Brain oxytocin receptors mediate ejaculation elicited by 7-hydroxy-2(di-N-propylamino) tetralin (7-OH-DPAT) in anaesthetized rats.
        Br J Pharmacol. 2008; 154: 1150-1159
        • Hellstrom W.J.
        Emerging treatments for premature ejaculation: Focus on dapoxetine.
        Neuropsychiatr Dis Treat. 2009; 5: 37-46
        • Hatzimouraditis K.
        • Eardley I.
        • Giuliano F.
        • et al.
        Erectile dysfunction and premature ejaculation.
        Eur Assoc Urol. 2013; : 38-48
        • Andersson K.-E.
        • Abdel-Hamid I.A.
        Therapeutic targets for premature ejaculation.
        Maturitas. 2011; 70: 26-33
        • Sansone A.
        • Romanelli F.
        • Jannini E.A.
        • Lenzi A.
        Hormonal correlations of premature ejaculation.
        Endocrine. 2015; 49: 333-338
        • Shinghal R.
        • Barnes A.
        • Mahar K.M.
        • et al.
        Safety and efficacy of Epelsiban in the treatment of men with premature ejaculation: a randomized, double-blind, placebo-controlled, fixed-dose study.
        J Sex Med. 2013; 10: 2506-2517
        • Clément P.
        • Bernabé J.
        • Compagnie S.
        • Alexandre L.
        • McCallum S.
        • Giuliano F.
        Inhibition of ejaculation by the non-peptide oxytocin receptor antagonist GSK557296 a multi-level site of action.
        Br J Pharmacol. 2013; 169: 1477-1485
        • Beaulieu J.-M.
        • Gainetdinov R.R.
        The physiology, signaling, and pharmacology of dopamine receptors.
        Pharmacol Rev. 2011; 63: 182-217
        • Safarinejad M.R.
        Relationship between premature ejaculation and genetic polymorphisms of the dopamine transporter gene (SLC6A3).
        BJU Int. 2011; 108: 292-296
        • Kitrey N.D.
        • Clément P.
        • Bernabé J.
        • Alexandre L.
        • Giuliano F.
        Microinjection of the preferential dopamine receptor D3 agonist 7-hydroxy-N,N-di-npropylaminotetralin hydrobromide into the hypothalamic medial preoptic area induced ejaculation in anesthetized rats.
        Neuroscience. 2007; 149: 636-641
        • Santtila P.
        • Jern P.
        • Westberg L.
        • et al.
        The dopamine transporter gene (DAT1) polymorphism is associated with premature ejaculation.
        J Sex Med. 2010; 7: 1538-1546
        • Giuliano F.
        • Clément P.
        Serotonin and premature ejaculation: from physiology to patient management.
        Eur Urol. 2006; 50: 454-466
        • Giuliano F.
        5-hydroxytryptamine in premature ejaculation: opportunities for therapeutic intervention.
        Trends Neurosci. 2006; 30: 79-84
        • Jeon H.-J.
        • Kim H.-S.
        • Lee C.-H.
        • Lee Y.-G.
        Candidate molecule for premature ejaculation, DA-8031: in vivo and in vitro characterization of DA-8031.
        Urology. 2011; 77: 17-21
        • Kang K.K.
        • Ahn G.J.
        • Sung J.H.
        • Kim S.H.
        • Kim H.
        • Lee S.
        Ejaculatory responses are inhibited by a new chemical entity, DA-8031, in preclinical rodent models of ejaculation.
        Urology. 2013; 81: 920.e13-920.e18
        • Xin Z.-C.
        • Zhu Y.-C.
        • Yuan Y.-M.
        • et al.
        Current therapeutic strategies for premature ejaculation and future perspectives.
        Asian J Androl. 2011; 13: 550-557
        • Jong T.R.
        • Pattij T.
        • Veening J.G.
        • et al.
        Citalopram combined with WAY 100635 inhibits ejaculation and ejaculation-related Fos immunoreactivity.
        Eur J Pharmacol. 2005; 509: 49-59
        • Yin T.L.
        • Yang J.
        • Zhang B.
        • et al.
        Folic acid supplementation as adjunctive treatment premature ejaculation.
        Med Hypotheses. 2011; 76: 414-416
        • Yan W.-J.
        • Yu N.
        • Yin T.-L.
        • Zou Y.-J.
        • Yang J.
        A new potential risk factor in patients with erectile dysfunction and premature ejaculation: folate deficiency.
        Asian J Androl. 2014; 16: 902-906
        • Zavatti M.
        • Zanoli P.
        • Benelli A.
        • Rivasi M.
        • Baraldi C.
        • Baraldi M.
        Experimental study on Satureja montana as a treatment for premature ejaculation.
        J Ethnopharmacol. 2011; 133: 629-633
        • Baraldi M.
        Using plant extracts for sexual disorders.
        (Italy Patent US; 7976878 B2; 12 July)2011
        • Carson C.
        • Wyllie M.
        Improved ejaculatory latency, control and sexual satisfaction when PSD502 is applied topically in men with premature ejaculation: results of a phase III, double-blind, placebo-controlled study.
        J Sex Med. 2010; 7: 3179-3189
        • Dinsmore W.W.
        • Wyllie M.G.
        PSD502 improves ejaculatory latency, control and sexual satisfaction when applied topically 5 min before intercourse in men with premature ejaculation: results of a phase III, multicentre, double-blind, placebo-controlled study.
        Authors J Compilation. 2009; 103: 940-949
        • Gilbert R.
        Promescent.
        (Absorption Pharmaceuticals, LLC; [Online]; Available from:) (Accessed May 1, 2015)
        • Mulhall J.
        • Stahl P.
        • Stember D.
        Premature ejaculation.
        in: Clinical Care Pathways in Andrology. Springer, New York2014: 141-149
        • Garcia F.
        • Capomacchia A.
        • Kongkeo S.
        • Brock G.
        Non-medical components are an importante factor in drug delivery in topical therapies: a study of topical lidocaine therapy for premature ejaculation.
        in: Proceedings of the 20th Annual Fall Scientific Meeting of the Sexual Medicine Society of North America. 2014 (Miami Beach, USA)
        • Dixon J.S.
        • Gosling J.A.
        The distribution of autonomic nerves in the musculature of the rat vas deferens. A light and electron microscope investigation.
        J Comparat Neurol. 1972; 146: 175-188
        • Sato Y.
        • Tanda H.
        • Nakajima H.
        • et al.
        Silodosin and its potential for treating premature ejaculation: a preliminary report.
        Int J Urol. 2012; 19: 268-272
        • Akin Y.
        • Gulmez H.
        • Ates M.
        • Bozkurt A.
        • Nuhoglu B.
        Comparison of alpha blockers in treatment of premature ejaculation: a pilot clinical trial.
        Iran Red Crescent Med J. 2013; 15: e13805
        • Birowo P.
        • Uckert S.
        • Kedia G.T.
        • et al.
        Characterization of the effects of various drugs likely to affect smooth muscle tension on isolated human seminal vesicle tissue.
        Urology. 2010; 75: 974-978
        • Abdel-Hamid I.A.
        Can smooth muscle represent a useful target for the treatment of rapid ejaculation?.
        Drugs Discov Today. 2005; 10: 1459-1466
        • Serefoglu E.C.
        • Silay M.S.
        Botulinum toxin-A injection may be beneficial in the treatment of life-long premature ejaculation.
        Med Hypotheses. 2010; 74: 83-84
        • Serefoglu E.C.
        • Hawley W.R.
        • Lasker G.F.
        • et al.
        Effect of Botulinum-A toxin injection into bulbospongiosus muscle on ejaculation latency in male rats.
        J Sex Med. 2014; 11: 1657-1663
        • Shi B.
        • Li X.
        • Chen J.
        • et al.
        Resiniferatoxin for treatment of lifelong premature ejaculation: a preliminary study.
        Int J Urol. 2014; 21: 923-926
        • Jannini E.A.
        • McMahon C.G.
        • Waldinger M.D.
        Premature Ejaculation: From Etiology to Diagnosis and Treatment.
        Springer, Italy2013
        • Althof S.E.
        • McMahon C.G.
        • Waldinger M.D.
        An update of the International Society of Sexual Medicine's guidelines for the diagnosis and treatment of premature ejaculation.
        J Sex Med. 2014; 11: 1392-1422